L. Frederick

发表

Sequence, expression and function of an mRNA encoding a soluble form of the human interleukin-6 receptor (sIL-6R).

J. Lust, D. Jelinek, N. Maihle, 1995, Current topics in microbiology and immunology.

and other p53-related genes in peripheral T-cell lymphomas TP63 Genome-wide analysis reveals recurrent structural abnormalities of

David I. Smith, I. V. Kovtun, Y. Asmann, 2012 .

Novel BCR-ABL1 fusion identified by targeted next-generation sequencing in a patient with an atypical myeloproliferative neoplasm.

D. Viswanatha, L. Frederick, Frank Beardell, 2014, Human pathology.

Inhibitory Effect of Pirfenidone on Glioblastoma Cell Lines: Implications for Treatment of Neurofibromatosis

C. James, J. Uhm, S. Kaufmann, 2007 .

Matrix metalloproteinase-10 is a critical effector of protein kinase Cι-Par6α-mediated lung cancer

D. Radisky, A. Fields, E. A. Thompson, 2008, Oncogene.

Analysis of EGF receptor amplicons reveals amplification of multiple expressed sequences

David I. Smith, C. James, Xiao-yang Wang, 1998, Oncogene.

Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer.

A. Fields, R. P. Regala, L. Frederick, 2007, Biochemical Society transactions.

Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.

David I. Smith, Sarah H. Johnson, I. V. Kovtun, 2012, Blood.

Genotype–phenotype correlation of hereditary erythrocytosis mutations, a single center experience

A. Tefferi, J. Hoyer, M. Patnaik, 2018, American journal of hematology.

TP53 mutations and polymorphisms in primary myelofibrosis

A. Tefferi, T. Lasho, R. Ketterling, 2011, American journal of hematology.

Genome-wide analysis reveals recurrent structural abnormalities of TP 63 and other p 53-related genes in peripheral T-cell lymphomas Running head : Genome-wide analysis of T-cell lymphomas

David I. Smith, Sarah H. Johnson, I. V. Kovtun, 2012 .

Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.

R. Kyle, S. Ansell, M. Gertz, 2016, American journal of clinical pathology.

Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow–Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?

R. Kyle, S. Ansell, M. Gertz, 2018, American journal of clinical pathology.

MyD-88 L265P MUTATIONS ARE PRESENT IN SOME CASES OF VITREORETINAL LYMPHOMA

J. Pulido, D. Salomão, D. Viswanatha, 2015, Retina.

Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations

M. Polley, Shaji K. Kumar, J. Fink, 2019, Blood Cancer Journal.

Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations

M. Polley, Shaji K. Kumar, R. Ketterling, 2019, Blood Cancer Journal.

Chemoimmunotherapy for relapsed/refractory and progressive 17p13‐deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low‐dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells

Deborah A. Bowen, T. Witzig, Wenting Wu, 2014, American journal of hematology.

Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders

P. Greipp, W. Morice, C. Hanson, 2007, Leukemia.